S.2104 - American Center for Cures Act of 2005109th Congress (2005-2006)
|Sponsor:||Sen. Lieberman, Joseph I. [D-CT] (Introduced 12/14/2005)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||Senate - 12/14/2005 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.2104 — 109th Congress (2005-2006)All Information (Except Text)
Introduced in Senate (12/14/2005)
American Center for Cures Act of 2005 - Amends the Public Health Service Act to establish within the National Institutes of Health (NIH) an American Center for Cures to promote translational research to speed the development of effective therapies, diagnostics, and cures.
Establishes a Cures Council to help advise and direct the Center's translational research efforts.
Authorizes the Center's Director (the Director of Cures) to establish Federally Funded Research and Development Centers to serve as research sites.
Establishes within the Center a Health Advanced Research Projects Agency to advance the development and deployment of critical health products. Authorizes the Agency to flexibly fund projects.
Requires the Director of Cures to establish a series of Centralized Institutional Review Boards to serve as human subject safety and well being custodians for multi-institutional clinical trials that are funded by public dollars.
Requires the Director of NIH to commission the Institute of Medicine to study the rules that protect patient safety and anonymity with respect to clinical research.
Establishes an Office of Bioscientific Enterprise Development (OBED) and transfers to it the Small Business Innovation Research and Small Business Technology Transfer programs. Requires OBED to partner grantees with potential purchasers of products.
Establishes an Office of Technology Transfer (OTT) and transfers to it appropriate NIH functions. Requires OTT to establish: (1) an Office of Rapid Access to Intervention Development to accelerate the process from laboratory to clinic; and (2) a program that cultivates industry interest in NIH-funded research.
Establishes an Office of Intramural Risk Opportunity and Mapping to oversee the intramural research programs of NIH.
Requires the Center for Biotechnology Information to develop new computational methods to aid in the processing of genomic data.
Provides for the construction of a clinical study registry and results database.